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1342 The Journal of Thoracic and CardBackground: Pulmonary thromboendarterectomy is an effective treatment for pa-
tients with chronic thromboembolic pulmonary hypertension. The early postopera-
tive course may be associated with pulmonary vasoconstriction and profound
systemic vasodilation. We investigated the potential involvement of endothelins in
these hemodynamic alterations.
Methods: Seventeen patients with chronic thromboembolic pulmonary hypertension
(pulmonary vascular resistance, 1015  402 dyne · s · cm5 [mean  SD]) under-
went pulmonary thromboendarterectomy with cardiopulmonary bypass and deep
hypothermic circulatory arrest. Peripheral arterial blood samples were drawn before
sternotomy, during cardiopulmonary bypass before and after deep hypothermic
circulatory arrest, and 0, 8, 16, and 24 hours after surgery and were analyzed for big
endothelin-1. The patients were divided into 2 groups according to whether their
preoperative big endothelin-1 plasma level was above or below the cutoff point of 2.1
pg/mL, as determined by receiver operating characteristic curve analysis (group A, big
endothelin-1 2.1 pg/mL, n  8; group B, big endothelin-1 2.1 pg/mL, n  9).
Results: Patients in group B, with higher preoperative big endothelin-1 levels (3.2
 1.0 pg/mL vs 1.5  0.4 pg/mL; P  .001), were poorer operative candidates
(preoperative mean pulmonary artery pressure, 51.3  7.1 mm Hg vs 43.6  6.2
mm Hg; P  .006) and had a poorer outcome (mean pulmonary artery pressure 24
hours after surgery, 32.6  9.5 mm Hg vs 21.8  6.2 mm Hg; P  .001). Positive
correlations were found between preoperative big endothelin-1 levels and preoper-
ative mean pulmonary artery pressure (r  0.56; P  .02) as well as postoperative
mean pulmonary artery pressure at 0 hours (r  0.70; P  .002) and 24 hours (r 
0.63; P  .006) after surgery. Preoperative big endothelin-1 levels predicted
outcome (postoperative mean pulmonary artery pressure at 24 hours after surgery)
after pulmonary thromboendarterectomy (area under the receiver operating charac-
teristic curve, 0.85). Peak big endothelin-1 levels also correlated with maximal
vasopressor dosage (r  0.65; P  .004).
Conclusions: Preoperative big endothelin-1 levels seem to correlate with the hemo-
dynamic alterations observed in pulmonary thromboendarterectomy and may be
used to predict hemodynamic outcome after pulmonary thromboendarterectomy.
Pulmonary thromboendarterectomy (PTE) has been shown to be the mosteffective therapeutic option in severe chronic thromboembolic pulmonaryhypertension (CTEPH), with a drastic improvement in pulmonary hemody-
namics and symptoms of heart failure.1-3 This procedure, however, is associated
with a mortality rate of 4% to 23%.1,4-9 In our experience with more than 180 cases,
we have seen marked hemodynamic instability during the initial phase. In approx-
imately 25% of patients, we observed a reversible component of pulmonary vaso-
constriction; in addition, there is profound systemic vasodilation that necessitates
iovascular Surgery ● November 2005
Langer et al Cardiopulmonary Support and Physiology
CS
Pintensive vasopressor support.10 Postoperative pulmonary hy-
pertension plays an important role in the occurrence of serious
complications such as reperfusion edema and hemoptysis.4-6,10
The underlying pathophysiological mechanisms of this hemo-
dynamic instability are poorly understood, but endogenous
substances released in response to heart failure, surgical
trauma, cardiopulmonary bypass (CPB), and deep hypother-
mic circulatory arrest (DHCA) may mediate the transient dis-
turbance of vascular tone.
Regulation of endothelin (ET) expression is at the level of
transcription, with stimuli including hypoxia, ischemia, shear
stress, and inflammatory mediators,11,12 and increased expres-
sion has been shown to be part of the physiologic response to
CPB.13 Circulating levels of ET-1 are increased in various
forms of pulmonary hypertension.14-16 When we observed
altered ET mediator and receptor expression in CTEPH,17 we
hypothesized that ETs as important vasoactive mediators may
be involved in the postoperative hemodynamic instability after
PTE. The aim of this investigation was to characterize ET
expression in response to PTE.
Methods
Patients
Seventeen consecutive patients underwent PTE for CTEPH (age,
55.9  8.9 years; 8 men; mean pulmonary artery pressure
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CPB  cardiopulmonary bypass
CTEPH  chronic thromboembolic pulmonary
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DHCA  deep hypothermic circulatory arrest
ET  endothelin
MPAP mean pulmonary artery pressure
PTE  pulmonary thromboendarterectomy
PVR  pulmonary vascular resistance
ROC  receiver operating characteristicarrest. *Disease type classification is according to Thistlethwaite and associat
The Journal of Thoracic[MPAP], 47.7  7.6 mm Hg; pulmonary vascular resistance
[PVR], 1015.4  401.8 dyne · s · cm5; New York Heart Associ-
ation [NYHA] class 3.3  0.5 [mean  SD]; Table 1). Seven
patients (age, 61.3  12.7 years; 2 men; normal MPAP; NYHA,
1.5  1.3) undergoing elective aortic arch replacement (partial
arch, n  2; total arch, n  5) under DHCA served as a control
group. The study was approved by the University Hospital Ethics
Review Committee, and informed consent was obtained from all
patients.
Surgical Procedure
After median sternotomy, the patients were placed on CPB by
bicaval and aortic cannulation and cooled to a nasopharyngeal
temperature of 18°C. Cardiac arrest was induced by infusion of
blood cardioplegia into the aortic root after aortic crossclamping.
The central pulmonary arteries were opened within the pericar-
dium, and a dissection plane was developed and followed to
segmental levels.7 Repeated periods of DHCA limited to 20 min-
utes were used to achieve accurate visualization during peripheral
dissection. After completion of PTE, CPB was resumed, and the
patient was rewarmed. Weaning from CPB was started after re-
warming to a rectal temperature of 34°C. Before pump flow was
reduced, the mean arterial blood pressure was regulated to approx-
imately 60 mm Hg by using an intravenous infusion of norepi-
nephrine if vascular resistance was low.10 Weaning from CPB was
accomplished by stepwise reduction of pump flow while monitor-
ing pulmonary artery pressures and administering volume care-
fully to maintain a cardiac index of more than 2.2 L · min1 · m2.
If MPAP exceeded 30 mm Hg, nitroglycerin was used as an
intravenous infusion to reduce preload.
For aortic arch replacement, the patients were also cooled to a
nasopharyngeal temperature of 18°C. Aortic replacement was per-
formed in standard fashion. Hemodynamic management during
weaning from CPB was identical to that in the PTE patients (CPB,
114 30 minutes; myocardial ischemia, 56 30 minutes; DHCA,
21  8 minutes).
ET Analysis
Arterial blood samples were drawn from the radial artery catheter
before surgery (after induction of anesthesia and line placement
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CSPproximately 28°C nasopharyngeal temperature) and after (rewarm-
ing period; approximately 28°C nasopharyngeal temperature)
DHCA, and 0, 8, 16, and 24 hours after arrival in the intensive care
unit. Blood samples were centrifuged at 1200 rpm for 10 minutes,
and the plasmatic supernatants were analyzed for the ET prohor-
mone big ET-1 by using a commercially available immunoassay
(Biomedica, Eching, Germany) with polyclonal capture and mono-
clonal detection antibodies highly specific for human big ET-1
(detection limit, 0.1 pg/mL).
Statistics
Data are shown as mean  SD. Nonparametric correlation (Spear-
man) was applied to correlate big ET-1 levels with hemodynamic
parameters and vasopressor support. The PTE patients had in-
creased preoperative big ET-1 levels (mean, 2.4  1.2 pg/mL).
Preoperative big ET-1 levels in the control group patients were
lower (1.3  1.2 pg/mL; P  .03). To further investigate the
correlation between preoperative big ET-1 levels and postopera-
tive MPAP, a receiver operating characteristic (ROC) curve
analysis18 was performed. A cutoff point of 2.1 pg/mL (sensitivity,
100%; specificity, 66.7%; Figure 1) was determined for the pre-
Figure 1. Big ET-1 levels during the perioperative course. Preop,
Preoperative; postop, postoperative; ARCH, aortic arch replacement.




Preoperative MPAP (mm Hg) 43.6
Preoperative PVR (dyne · s · cm5) 829
0-h postoperative MPAP (mm Hg) 24.3
0-h postoperative PVR (dyne · s · cm5) 390
24-h postoperative MPAP (mm Hg) 21.8
24-h postoperative PVR (dyne · s · cm5) 254
Data are expressed as mean  SD. ET, Endothelin; MPAP, mean pulmon
repeated-measures analysis of variance and Bonferroni multiple t test post hoc
1344 The Journal of Thoracic and Cardiovascular Surgery ● Novdiction of increased postoperative MPAP (defined by postopera-
tive MPAP 30 mm Hg 24 hours after surgery) by increased
preoperative big ET-1 levels. The patients were then divided into
2 groups according to whether the preoperative ET-1 level was
below or above this cutoff point (group A, big ET-1 2.1 pg/mL,
n  8; group B, big ET-1 2.1 pg/mL, n  9). Statistical
differences between groups were assessed with a t test, 2 test, or
2-way repeated-measures analysis of variance (MPAP and PVR)
by using standard software (SigmaStat 2.0; Jandel Scientific, San
Rafael, Calif). If the analysis of variance yielded a significant F
value (P .05), then the Bonferroni multiple t test was applied for
post hoc testing.
Results
In both PTE groups, big ET-1 reached comparable peak
levels in response to the operative procedure (group A, 4.9 
1.2 ng/mL; group B, 5.4  1.3 ng/mL) and declined to
similar levels within 24 hours after surgery. Patients in the
control group had similar levels during the postoperative
course (Figure 1).
Preoperative MPAP (51.3  7.1 mm Hg vs 43.6  6.2
mm Hg; P  .006) and PVR (1180  383 dyne · s · cm5
vs 829  356 dyne · s · cm5; P  .001) were higher in
group B (Table 2), even though there were no differences in
demographic data. Times for CPB, myocardial ischemia,
and DHCA were similar in both PTE groups (Table 1).
MPAP (P  .001) and PVR (P  .001) were normalized
after surgery in group A. Patients in group B showed a
marked decrease in MPAP (P  .001) and PVR (P  .001)
compared with the preoperative values but had residual
pulmonary hypertension (Table 2). Two patients in group B
died in the early postoperative course as a result of multiple
organ failure (n  1) and massive reperfusion edema (n 
1); their big ET-1 reached high peak levels of 6.1 and 6.2
pg/mL. The patient with reperfusion edema died at his
individual peak big ET-1-level. All other patients were
discharged from the hospital.
Preoperative big ET-1 levels correlated with preopera-
tive MPAP (r  0.56; P  .02; Figure 2, A) and preoperative
PVR (r  0.52; P  .03), as well as postoperative MPAP
immediately after surgery (r  0.70; P  .002; Figure 2, B)
2.1 pg/mL)
Group B
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Pand 24 hours after surgery (r  0.63; P  .006; Figure 2,
C). In addition, the ROC curve analysis demonstrated that
an increase of preoperative big ET-1 was a good predictor
of poor hemodynamic outcome after PTE (postoperative
MPAP 30 mm Hg 24 hours after surgery: area under the
curve [AUC], 0.85; Figure 3; postoperative PVR 500
dyne · s · cm5: AUC, 0.77).
High vasopressor support with norepinephrine was re-
quired during the early postoperative course (group A, 0.4
 0.4 g · kg1 · min1; group B, 0.6  0.5 g · kg1 ·
min1) in both PTE groups, whereas only moderate vaso-
pressor support was necessary in the control group (0.1 
0.2 g · kg 1 · min1). It is interesting to note that a pos-
itive correlation was found between peak big ET-1 levels
Figure 2. A, Correlation between preoperative (preop)
preoperative big ET-1 and MPAP 24 hours after surger
Figure 3. Receiver operating characteristic curve (AUC, area
under the curve) of preoperative big ET-1 level to predict post-
operative MPAP.
The Journal of Thoracicand the maximal norepinephrine administration after sur-
gery (r  0.65; P  .004; Figure 4) in PTE patients.
Discussion
CTEPH portends a poor prognosis.2,19 Almost all patients
are in NYHA stage III or IV at the time of diagnosis and
operation.1,2 PTE as the most effective therapeutic approach
in severe CTEPH has been demonstrated to drastically
improve pulmonary hemodynamics and eliminate heart fail-
ure.1-3 This challenging surgical procedure, however, is
associated with a mortality rate of 4% to 23%.1,4-9,20 Several
investigators have previously tried to identify risk factors to
predict the outcome of CTEPH patients after PTE and found
that the severity of disease was associated with periopera-
tive mortality.1,4-6,8 We have seen a reversible component
of pulmonary vasoconstriction in the early postoperative
course (48 hours) in a significant proportion of patients
that may trigger lethal complications such as fulminant
reperfusion edema and hemoptysis.2,4,21 In parallel, pro-
found systemic vasodilatation is frequently observed, and
this necessitates intensive vasopressor support to maintain
ET-1 and preoperative MPAP. B, Correlation between
stop).
Figure 4. Correlation between peak big ET-1 and maximal vaso-big
y (popressor dosage.
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CSPadequate systemic blood pressure.10 The underlying patho-
physiological mechanisms of these hemodynamic alter-
ations have not yet been elucidated.
A threefold to sixfold increase of systemic ET levels has
been observed immediately after cardioplegic arrest and
reperfusion in standard cardiac surgical procedures.13 Be-
cause PTE is a major insult to the pulmonary vascular
endothelium and requires long CPB and DHCA times,1,7 an
increased ET release should be expected. ET activity has
also been shown to be increased in various forms of pul-
monary hypertension14-16 and correlates with the severity of
disease in patients with primary pulmonary hypertension.22
Because we have found increased big ET-1 levels and
altered receptor expression in patients with CTEPH,17 we
hypothesized that the ET system might be involved in these
hemodynamic alterations in the early postoperative course
after PTE. To eliminate the confounding factor of big ET-1
release in response to CPB and DHCA, we also determined
big ET-1 levels in patients with aortic arch replacement.
ETs are synthesized as preprohormones and posttransla-
tionally processed to vasoactive peptides.23 Big ET-1 is the
39–amino acid prohormone with approximately 1% of the
vasoactive potency of ET-1.23 After cleavage by the ET-
converting enzyme,23 functional ET-1 regulates vascular
tone through binding to its cellular receptors.11,12 ET-A
receptors are expressed primarily on vascular smooth mus-
cle cells and mediate a profound vasoconstriction and pro-
liferation.11,12 In the normal pulmonary vasculature, ET-B
receptors are predominantly located on endothelial cells and
promote vasodilation via increased nitric oxide and prosta-
cyclin production, as well as inhibition of the ET-converting
enzyme and pulmonary clearance of ET-1.11,12,24 Nitric
oxide and prostacyclin also negatively feed back on the ET
mediator system by inhibition of prepro–ET-1 transcription.
In the pathologic setting of pulmonary hypertension,24 how-
ever, a subpopulation of ET-B receptors located on vascular
smooth muscle cells may actually contribute to vasocon-
striction,25,26 possibly as a result of upregulation of ET-B
receptors. Kim and colleagues27 documented an increased
intensity of ET-A and ET-B receptor activity in a rat model
of chronic unilateral pulmonary artery ligation, and upregu-
lation of ET-B receptor expression has been observed in the
pulmonary arteries of patients with CTEPH17 and primary
pulmonary hypertension.28 Thus, there is increasing evi-
dence that the hemodynamic effects of ET-1 depend on the
differential expression and localization of ET receptor sub-
types, which vary among disease types.24 ET-1 may there-
fore result in predominant vasoconstriction or vasodilation.
Our current investigation documented a positive correla-
tion between preoperative big ET-1 levels and the severity
of disease in CTEPH, which has not been reported previ-
ously. It is interesting to note that preoperative big ET-1 levels
also correlated with postoperative MPAP, even though post-
1346 The Journal of Thoracic and Cardiovascular Surgery ● Novoperative circulating big ET-1 levels were similarly low in
all patients. (The only exception was the patient who died
from reperfusion edema at his individual peak big ET-1
level.) This was supported by the ROC curve analysis,
which provides a method for synthesizing the sensitivity
and specificity of a diagnostic test across a spectrum of
possible cutoff points. The AUC can be interpreted as the
probability of a correct prediction.18 Preoperative big ET-1
levels may thus serve as a predictor of outcome after PTE in
selected cases when patient selection remains difficult with
the standard diagnostic tools, eg, right heart catheterization,
pulmonary angiography, computed tomography, and venti-
lation/perfusion scintigraphy.1,29
The need for vasopressor support is common in cardiac
operations, especially in procedures that necessitate long
CPB times and DHCA. In concordance with this general
experience, our control group also required vasopressor
support. However, the dose of vasopressor support required
in PTE patients was increased fourfold to fivefold. The
reason for this profound vasodilation or decreased response
to vasopressors is still unclear. It is interesting to note that
our data suggest that the ET system may be involved in the
regulation of systemic vascular tone early after PTE. Peak
plasma levels of big ET-1 correlated with the maximal
vasopressor dosage required within the first 24 hours after
surgery. This may be due to downregulation of ET-A re-
ceptors in the systemic circulation, as seen in patients with
primary pulmonary hypertension as an adaptive response to
increased levels of ET-1.28
In summary, our data suggest an active role of the ET
system in the pathophysiology of CTEPH. Preoperative big
ET-1 levels correlate with the severity of CTEPH and may
allow prediction of hemodynamic instability and poor out-
come after PTE. Because we saw similar levels of the
vasoactive mediator in response to the operative procedure,
differences in vascular tone after PTE may involve altered
receptor expression and distribution in patients with ad-
vanced CTEPH, even though our current data do not pro-
vide proof this hypothesis. Future research will have to
address both pulmonary and systemic circulation to charac-
terize a presumptive heterogeneity in receptor expression
and distribution, as well as other relevant mediator systems.
We thank Filiberto Rodriguez, MD, and Katherine B. Har-
rington, BA (Stanford University, Stanford, Calif), for assistance
with the manuscript.
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